Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-24
2006-01-24
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S236800
Reexamination Certificate
active
06989381
ABSTRACT:
There is provided a pharmaceutical composition for therapeutic or prophylactic administration to a subject having an infective disease or condition or at risk thereof. The composition comprises an aqueous carrier having in solution therein (a) an oxazolidinone antimicrobial drug, for example linezolid, in a therapeutically or prophylactically effective drug concentration that is above the practical limit of solubility of the drug in a substantially isotonic aqueous solution at a physiologically compatible pH, and (b) a pharmaceutically acceptable cyclodextrin compound in a concentration sufficient to maintain the drug in solution at such a drug concentration. The composition is particularly useful for intravenous delivery of the drug.
REFERENCES:
patent: 4524068 (1985-06-01), Szejtli et al.
patent: 4599327 (1986-07-01), Nógrádi et al.
patent: 4727064 (1988-02-01), Pitha
patent: 5024998 (1991-06-01), Boder
patent: 5134127 (1992-07-01), Stella et al.
patent: 5164510 (1992-11-01), Brickner
patent: 5231188 (1993-07-01), Brickner
patent: 5324718 (1994-06-01), Loftsson
patent: 5376645 (1994-12-01), Stella et al.
patent: 5486508 (1996-01-01), Uda et al.
patent: 5538721 (1996-07-01), Babcock et al.
patent: 5565571 (1996-10-01), Barbachyn et al.
patent: 5627181 (1997-05-01), Riedl et al.
patent: 5646294 (1997-07-01), Bartroli et al.
patent: 5652238 (1997-07-01), Brickner et al.
patent: 5670530 (1997-09-01), Chen et al.
patent: 5688792 (1997-11-01), Barbachyn et al.
patent: 5698574 (1997-12-01), Riedl et al.
patent: 5756546 (1998-05-01), Pirotte et al.
patent: 5807895 (1998-09-01), Stratton et al.
patent: 5824668 (1998-10-01), Rubinfeld et al.
patent: 5837870 (1998-11-01), Pearlman et al.
patent: 5874418 (1999-02-01), Stella et al.
patent: 5910504 (1999-06-01), Hutchinson
patent: 6046177 (2000-04-01), Stella et al.
patent: 6069145 (2000-05-01), Betts
patent: 6133248 (2000-10-01), Stella
patent: 6284747 (2001-09-01), Rubinfeld
patent: 6316020 (2001-11-01), Whittle et al.
patent: 6337329 (2002-01-01), Cochran et al.
patent: 6407079 (2002-06-01), Müller et al.
patent: 2002/0156072 (2002-10-01), Barbachyn et al.
patent: 0 340 171 (1989-11-01), None
patent: WO 85/02767 (1985-07-01), None
patent: WO 96/32135 (1996-10-01), None
patent: WO 96/38175 (1996-12-01), None
patent: WO 97/36935 (1997-10-01), None
patent: WO 97/39770 (1997-10-01), None
patent: WO 98/37884 (1998-09-01), None
patent: WO 98/55148 (1998-12-01), None
patent: WO 98/58677 (1998-12-01), None
patent: WO 99/24073 (1999-05-01), None
patent: WO 99/24393 (1999-05-01), None
patent: WO 99/27932 (1999-06-01), None
patent: WO00/18387 (2000-04-01), None
patent: WO01/19366 (2001-03-01), None
patent: WO02/30395 (2002-04-01), None
Bekers et al. Drug Development and Industrial Pharmacy. 17, 1503-1549. (1991).
Loftsson. Pharmazie. 53, 733-740. (1998).
Rajewski. Pharmaceutical Applications of Cyclodextrins. In Journal of Pharmaceutical Sciences. 85(11), pp. 1154-1159. (1996).
SzejtliCyclodextrins and Their Inclusion Complexes. Chinoin Research Center, Hungary. pp. 204-232. (1982).
Szejtli. Medical Research Reviews. 14, 353-386. (1994).
Zhang et al. Expert Opinion on Therapeutic Patents. 9, 1697-1717. (1999).
Arima et al., (2001), Comparative Studies of the Enhancing Effects of Cyclodextrins on the Solubility and Oral Bioavailibility of Tacrolimus in Rats,Journal of Pharmaceutical Sciences, vol. 90, No. 6, pp. 690-701.
Conners, (1997), The Stability of Cyclodextrin Complexes in Solution,Chem. Rev.97, pp. 1325-1357.
Faucci et al., (2002), Computer-aided molecular modeling techniques for predicting the stability of drug-cyclodextrin inclusion complexes in aqueous solutions, 358, pp. 383-390.
Lipkowitz, (1998), Applications of Computational Chemistry to the Study of Cyclodextrins,Chem. Rev., 98, ppo. 1829-1873.
Lotsson et al., (1989), Effects of 2-hydroxpropyl-β-cyclodextrin on the aqueous solubility of drugs and transdermal delivery of 17β-estradiol,Acta Pharm. Nord., 1(4), pp. 185-194.
Loftsson, et al., (1991), Solubilization and stabilization of drugs through cyclodextrin complexation,Act Pharm. Nord., 3(4), pp. 215-217.
Loftsson et al., (1996), Pharmaceutical Applications of Cyclodextrins. 1. Drug Soulubilization and Stabilization,Journal of Pharmaceutical Sciences, vol. 85, No. 10, pp. 1017-1025.
Pagington, (1987), β-Cyclodextrin: the success of molecular inclusion,Chemistry in Britain, pp. 455-458.
Pitha et al., (1983), Molecular Encapsulation of Drugs By Cyclodextrins And Congeners,Controlled Drug Delivery, vol. 1, pp. 125-148.
Pitha et al., (1986), Hydroxypropyl-β-cyclodextrin: preparation and characterization; effects on solubility of drugs,International Journal of Pharmaceutics, 29, pp. 73-82.
Schneider et al., (1998), NMR Studies of Cyclodextrins and Cyclodextrin Complexes,Chem. Rev., 98, pp. 1755-1785.
Stella, (1997), Cyclodextrins: Their Future in Drug Formulation and Delivery,Pharmaceutical Research, vol. 14, No. 5, pp. 556-567.
Szejtli, (1998), Introduction and General Overview of Cyclodextrin Chemistry,Chem. Rev., 98, pp. 1743-1753.
Uekama, (1987), Cyclodextrin Inclusion Compounds: Effects on Stability and Bio-Pharmaceutical Properties,Topics in Pharmaceutical Sciences, pp. 181-194.
Uekama et al., (1987), Cyclodextrins in Drug Carrier Systems,Critical Reviews in Therapeutic Drug Carrier Systems, 3(1), pp. 1-40.
Uekama et al., (1998), Cyclodextrin Drug Carrier System,Chem. Rev., 98, pp. 2045-2076.
Hilliard, (1999), The Complexation of Hydroxypropyl-β-Cyclodextrin with Oxazolidinones: A Study on the Effect of Cyclodextrins in Terms of Solubility Enhancement, Increased Dissolution Rate, and Precipitation Inhibition.
Ashbrook Charles W.
Delacroix-Muirheid C.
King Karen B.
Low Christopher S. F.
Pharmacia Corporation
LandOfFree
Solution composition of an oxazolidinone antibiotic drug... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Solution composition of an oxazolidinone antibiotic drug..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Solution composition of an oxazolidinone antibiotic drug... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3524858